Evidence map›Paper›PMID 38491821›Full record

Trial reportCancer medicine2024

EXERT-BC: A pilot study of an exercise regimen designed to improve functional mobility, body composition, and strength after the treatment for breast cancer.

David J Carpenter, Chris Peluso, Christie Hilton, Frank Velasquez, Adam Annichine, Krista Matsko, Jared Rosenberg, Alexander K Diaz, Parker Hyde, Sushil Beriwal and 1 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Development of a breast reconstruction-specific computational model to predict shoulder function in breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

David J CarpenterDepartment of Radiation Oncology, Wellstar Paulding Medical Center, Hiram, Georgia, USA.
Chris PelusoExercise Oncology Consortium, Pittsburgh, Pennsylvania, USA.
Christie HiltonDepartment of Medical Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Frank VelasquezAllegheny Health Network Sports Performance Center, Pittsburgh, Pennsylvania, USA.
Adam AnnichineDepartment of Radiation Oncology, Wellstar Paulding Medical Center, Hiram, Georgia, USA.
Krista MatskoAllegheny Health Network Sports Performance Center, Pittsburgh, Pennsylvania, USA.
Jared RosenbergDepartment of Exercise Science, Syracuse University, Syracuse, New York, USA.
Alexander K DiazDepartment of Radiation Oncology, Murray-Calloway County Hospital, Murray, Kentucky, USA.
Parker HydeDepartment of Kinesiology, Northern Georgia University, Dahlonega, Georgia, USA.
Sushil BeriwalDepartment of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Colin E ChampExercise Oncology Consortium, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-1879-7463
Allegheny Health Network · USWellStar Health System · USMurray State University · USSyracuse University · USUniversity of North Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeResistance training may offer several unique advantages within breast cancer (BC) survivorship care; however, safety concerns have limited the application of high-intensity compound movements necessary to elicit optimal changes in body composition, strength, and quality of life in this population. The EXERT-BC trial assesses the safety and feasibility of an evidence-based, dose-escalated resistance training regimen among BC survivors, with the goal of improving physical and metabolic function, mobility, muscle mass, and body composition.

methodsParticipants included women with breast cancer underwent a 3-month thrice weekly exercise regimen involving dose escalation of high-intensity compound exercises. Coprimary outcomes included safety and adherence. Pre- and post-regimen assessment included body composition testing, functional mobility and balance, total load (weight × repetitions × sets) across compound exercises, and patient reported quality of life. Pairwise comparison was performed via the paired t test.

resultsFourty participants completed a 3-month exercise regimen, with a median age of 57 years (range, 27-74 years) and 73% having stage 0-2 BC. BC therapies concurrent with exercise included anti-estrogen therapy (80%), radiotherapy (30%), and non-hormonal systemic therapy (15%). No adverse events were observed aside from a single case of self-limited knee pain. Session attendance exceeded a prespecified threshold of 75%, and 98% patients reported ongoing compliance to an exercise regimen following regimen completion. Significant reductions in percent body fat (p < 0.001) and increases in percent muscle mass (p = 0.011) were observed. Significant increases in resting metabolic rate (p = 0.023), bilateral grip strength (p < 0.001), functional movement screen (p < 0.001), bilateral Y-Balance testing (p < 0.001), and Godin questionnaire scores (p < 0.001) were observed.

conclusionA 3-month dose-escalated resistance training regimen comprising high-intensity compound movements appears safe with a high degree of adherence among breast cancer survivors, resulting in demonstrable improvements in body composition, metabolic parameters, strength increases, and patient-reported quality of life.

Indexed as

Breast NeoplasmsAdultAgedBody CompositionExercise TherapyFemaleHumansMiddle AgedMuscle StrengthPilot ProjectsQuality of Lifebody compositionbreast cancerexercise sciencehypertrophyresistance training

Identifiers

PMID38491821
PMCPMC10943368
OpenAlexW4392888696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.